Live Ownership Coverage: Bristol Myers Squibb Co’s (NYSE:BMY) Sentiment is 1.13

November 24, 2016 - By Marguerite Chambers   ·   0 Comments

Live Ownership Coverage: Bristol Myers Squibb Co's (NYSE:BMY) Sentiment is 1.13

Sentiment for Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) institutional sentiment increased to 1.13 in 2016 Q2. Its up 0.19, from 0.94 in 2016Q1. The ratio improved, as 556 institutional investors increased and opened new holdings, while 589 sold and reduced holdings in Bristol Myers Squibb Co. The institutional investors in our partner’s database now possess: 1.19 billion shares, down from 1.23 billion shares in 2016Q1. Also, the number of institutional investors holding Bristol Myers Squibb Co in their top 10 holdings increased from 67 to 95 for an increase of 28. Sold All: 47 Reduced: 542 Increased: 472 New Position: 84.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has a market cap of $94.54 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 28.26 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.

The stock increased 0.35% or $0.2 on November 23, hitting $56.75. About 10.16M shares traded hands. Bristol-Myers Squibb Co (NYSE:BMY) has declined 19.71% since April 22, 2016 and is downtrending. It has underperformed by 25.12% the S&P500.

Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on January, 26. They expect $0.65 EPS, up 71.05% or $0.27 from last year’s $0.38 per share. BMY’s profit will be $1.08B for 21.83 P/E if the $0.65 EPS becomes a reality. After $0.77 actual EPS reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -15.58% negative EPS growth.

According to Zacks Investment Research, “Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.”

Venbio Select Advisor Llc holds 7.28% of its portfolio in Bristol-Myers Squibb Co for 445,339 shares. Winch Advisory Services Llc owns 70,379 shares or 6.28% of their US portfolio. Moreover, Crossvault Capital Management Llc has 5.82% invested in the company for 111,902 shares. The New Jersey-based Blackhill Capital Inc has invested 5.55% in the stock. Rtw Investments Llc, a New York-based fund reported 209,701 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 5 sales for $6.86 million net activity.

Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage

Ratings analysis reveals 31% of Bristol-Myers Squibb Company’s analysts are positive. Out of 16 Wall Street analysts rating Bristol-Myers Squibb Company, 5 give it “Buy”, 3 “Sell” rating, while 8 recommend “Hold”. The lowest target is $52 while the high is $80. The stock’s average target of $68.90 is 21.41% above today’s ($56.75) share price. BMY was included in 34 notes of analysts from July 28, 2015. The stock has “Market Perform” rating given by BMO Capital Markets on Monday, January 25. The firm has “Buy” rating by UBS given on Friday, April 29. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Underweight” rating by Atlantic Securities on Friday, December 18. Hilliard Lyons initiated the stock with “Neutral” rating in Monday, May 23 report. The firm has “Equal Weight” rating given on Tuesday, December 1 by Barclays Capital. The company was maintained on Tuesday, September 20 by Citigroup. The company was maintained on Monday, May 9 by Credit Suisse. The firm has “Buy” rating by Berenberg given on Friday, January 22. The firm has “Equal-Weight” rating given on Friday, September 9 by Barclays Capital. Piper Jaffray upgraded the shares of BMY in a report on Monday, August 24 to “Underweight” rating.

BMY Company Profile

Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

More news for Bristol-Myers Squibb Co (NYSE:BMY) were recently published by: Wsj.com, which released: “Bristol-Myers Squibb Makes Moves to Reassure Investors” on October 27, 2016. Businesswire.com‘s article titled: “Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration …” and published on November 16, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>